A Study to Evaluate the Absolute Bioavailability of BMS-986205 Tablet Formulation
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2018
Price : $35 *
At a glance
- Drugs Linrodostat (Primary) ; Linrodostat (Primary)
- Indications Bladder cancer; Cancer; Head and neck cancer; Malignant melanoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 21 Mar 2018 Status changed from recruiting to completed.
- 19 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Feb 2018.
- 19 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Feb 2018.